What Do Wisconsin Records Reveal About Ozempic and Gastroparesis?
From General Health to Specific Drug Risks
If you or someone you know is taking Ozempic and experiencing persistent nausea, vomiting, or abdominal pain, you may be wondering if the medication is linked to gastroparesis—a condition where the stomach empties too slowly. For decades, pharmacovigilance systems have tracked adverse events to identify such connections, building a body of evidence that now includes reports from Wisconsin. This page examines those records and what they mean for patients and healthcare providers.
Understanding Ozempic and Its Gastrointestinal Effects
Ozempic (semaglutide) is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in higher doses, for chronic weight management. Among its known adverse effects, gastrointestinal reactions are prominent and have been documented in clinical trials. In the pool of placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation. More patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In the trial with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).
Gastroparesis: Definition and Diagnosis
Gastroparesis is a disorder characterized by delayed gastric emptying in the absence of mechanical obstruction, leading to symptoms such as nausea, vomiting, early satiety, postprandial fullness, and abdominal pain. Clinical diagnosis typically involves gastric emptying scintigraphy, breath tests, or wireless motility capsules. The condition can be idiopathic or secondary to diabetes, postsurgical changes, or medication effects. The mechanistic pathways linking Ozempic to gastroparesis involve the drug's action as a GLP-1 receptor agonist, which slows gastric emptying as part of its therapeutic effect on glycemic control. This pharmacodynamic property can become pathological in susceptible individuals, leading to symptomatic gastroparesis.
Reported Gastrointestinal Adverse Reactions with Ozempic
The reported gastrointestinal adverse reactions with Ozempic include dyspepsia (placebo 1.9%, 0.5 mg 3.5%, 1 mg 2.7%), eructation (placebo 0%, 0.5 mg 2.7%, 1 mg 1.1%), flatulence (placebo 0.8%, 0.5 mg 0.4%, 1 mg 1.5%), gastroesophageal reflux disease (placebo 0%, 0.5 mg 1.9%, 1 mg 1.5%), and gastritis (placebo 0.8%, 0.5 mg 0.8%, 1 mg 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While gastroparesis is not explicitly listed in these trial data, the constellation of symptoms and the known effect on gastric motility support a plausible link.
Risk Considerations and Labeling Gaps
Risk considerations for patients who develop gastroparesis after Ozempic use center on the adequacy of warnings. The prescribing information for Ozempic includes a section on hypersensitivity reactions, noting that serious hypersensitivity reactions (e.g., anaphylaxis, angioedema) have been reported in patients treated with Ozempic (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the label does not specifically warn about gastroparesis as a distinct adverse reaction. The gastrointestinal adverse reactions are described in terms of nausea, vomiting, diarrhea, and other symptoms, but the potential for delayed gastric emptying leading to gastroparesis is not explicitly highlighted. This gap in labeling may affect the ability of patients and healthcare providers to recognize and mitigate the risk early.
Settlement Criteria for Affected Patients
Settlement-related considerations for affected patients involve establishing a causal link between Ozempic exposure and the development of gastroparesis. Key factors include the timeline between exposure and documented harm. In clinical trials, gastrointestinal adverse reactions occurred more frequently during dose escalation, suggesting that the onset of symptoms may be temporally related to initiation or dose increases (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). For patients who develop persistent gastroparesis symptoms after starting Ozempic, the temporal relationship is a critical element. Additionally, the severity of symptoms leading to discontinuation—3.1% for 0.5 mg and 3.8% for 1 mg—indicates that a subset of patients experiences significant gastrointestinal distress (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). For settlement purposes, documentation of the onset of symptoms relative to Ozempic use, medical records confirming a diagnosis of gastroparesis, and exclusion of other causes (e.g., diabetic gastroparesis, idiopathic causes) are essential.
Mechanistic Plausibility and Evidence Summary
The mechanistic pathway linking Ozempic to gastroparesis is supported by the drug's known effect on gastric emptying. GLP-1 receptor agonists like semaglutide delay gastric emptying, which can exacerbate or unmask underlying gastroparesis. The reported gastrointestinal adverse reactions, including dyspepsia and gastroesophageal reflux disease, are consistent with altered gastric motility (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While the label does not list gastroparesis as a specific adverse reaction, the clinical presentation of severe, persistent nausea, vomiting, and abdominal distension in patients on Ozempic should prompt evaluation for gastroparesis. In summary, the evidence from clinical trials indicates a higher incidence of gastrointestinal adverse reactions with Ozempic compared to placebo, with dose-dependent effects. The lack of explicit warning about gastroparesis in the prescribing information may be a point of contention in litigation. Patients seeking settlement should gather medical records documenting the timeline of Ozempic use, onset of gastroparesis symptoms, diagnostic test results, and any discontinuation of the drug due to adverse effects. The mechanistic plausibility and temporal relationship are central to establishing harm.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the Ozempic gastroparesis settlement?
The Ozempic gastroparesis settlement refers to legal claims brought by individuals who developed gastroparesis after using Ozempic (semaglutide). These lawsuits allege that the manufacturer failed to adequately warn about the risk of gastroparesis. Settlement criteria typically require documented Ozempic exposure, a confirmed gastroparesis diagnosis, and a temporal relationship between drug use and symptom onset.
What evidence is needed to qualify for the settlement?
To qualify, patients need medical records showing Ozempic prescription and use, a diagnosis of gastroparesis confirmed by gastric emptying tests (e.g., scintigraphy), documentation of symptom onset after starting Ozempic, and exclusion of other causes such as diabetic gastroparesis or idiopathic conditions. Discontinuation of Ozempic due to gastrointestinal adverse effects strengthens the claim.
Does Ozempic's label warn about gastroparesis?
No, the current prescribing information for Ozempic does not explicitly list gastroparesis as a specific adverse reaction. It mentions gastrointestinal adverse reactions like nausea, vomiting, and diarrhea, but does not warn about delayed gastric emptying leading to gastroparesis. This labeling gap is a key issue in litigation.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
Related Articles
References
Request a Free Case Review
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.